Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
dinutuximab beta + GPOH chemotherapy
- Development stage
- Unknown
- Lead developer
- Princess Máxima Center for Pediatric Oncology
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Administration
- Intravenous
01
Overview
Dinutuximab beta + GPOH chemotherapy is a combination treatment regimen currently under clinical investigation for the induction phase of newly diagnosed high-risk neuroblastoma. The regimen consists of dinutuximab beta (Qarziba), a chimeric monoclonal antibody targeting the disialoganglioside GD2, and the GPOH (German Pediatric Oncology and Hematology Group) induction chemotherapy protocol. Dinutuximab beta exerts its antitumor effect by binding to GD2 on the surface of neuroblastoma cells, thereby triggering antibody-dependent cell-mediated cytotoxicity (ADCC) and complement-dependent cytotoxicity (CDC). The GPOH chemotherapy component typically involves intensive cycles of cytotoxic agents such as cisplatin, etoposide, vindesine, cyclophosphamide, and doxorubicin. This combination is being evaluated in the Phase Ib SIOPEN-Pilot01 trial, sponsored by the Princess Maxima Center for Pediatric Oncology, to establish the safety and recommended dose of integrating anti-GD2 immunotherapy into intensive induction chemotherapy.
- Brand names
- Qarziba
- Other names
- GPOH-Princess Maxima Center for Pediatric Oncology-neuroblastomaDinutuximab beta + GPOH regimenDB + GPOH
02
Targets
DNATUBB (Tubulin (alpha and beta subunits))TOP2A (DNA topoisomerase II)GD2
Beyond the preview
Go deeper on dinutuximab beta + GPOH chemotherapy.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on dinutuximab beta + GPOH chemotherapy.